Findings highlight MiraDx’s mirSNP platform as a novel approach for assessing treatment-related toxicity risk and response to cancer therapies LOS ANGELES, CA –May 22, 2025 — MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, today announced two studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, […]
Read MoreLOS ANGELES, CA – APRIL 7, 2025 – MiraDx, a molecular diagnostics company advancing personalized medicine through novel germline biomarkers, announced a groundbreaking study published in the journal Clinical Cancer Research, validating previous findings that its PROSTOX ultra test can predict long-term side effects from radiation therapy for prostate cancer, prior to starting treatment. Led […]
Read MoreThis year, approximately 300,000 men in the U.S. were diagnosed with prostate cancer, bringing the total to over 3.3 million cases.1 Nearly half of those with localized prostate cancer undergo radiation therapy, including stereotactic body radiation therapy (SBRT). However, about 16% of men treated with SBRT develop genitourinary (GU) toxicity within three to six months […]
Read MoreAs definitive treatments for localized prostate cancer are highly effective, post-treatment quality of life has become a key consideration in patient-physician shared decision-making.1 A significant side effect of definitive radiotherapy is late grade ≥ 2 genitourinary (GU) toxicity—typically presenting three to six months after treatment as urinary frequency, urgency, or incontinence—which affects approximately 15% of […]
Read More